BLRX News and Press, BioLineRx Ltd. From 03/16/22

BioLineRx Reports Year-End 2021 Financial Results and Provides Corporate Update - Commercial assessment commissioned indicating US stem-cell mobilization opportunity of ~$360m - Successful pre-NDA meeting with FDA; NDA submission anticipated in mid-2022 - Announced highl...

BioLineRx to Report 2021 Annual Results on March 16, 2022 Management to hold a conference call at 10:00 a.m. EST PR Newswire TEL AVIV, Israel , March 10, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX), (TASE: BLRX), a late clinical-stage biopharmaceu...

Announcing additional data from a follow-on study based on its Phase 3 GENESIS trial, BioLineRx (BLRX +3.5%) touted the economic benefits of motixafortide, its experimental agent for stem cell mobilization (SCM) The supplemental analysis performed by the Global Health Economics and Outcomes R...

Indonesia Energy (NYSE:INDO) +46%. Imperial Petroleum (NASDAQ:IMPP) +20%. DBV Technologies (NASDAQ:DBVT) +19%. Canaan (NASDAQ:CAN) +18% on Q4 results. Cedar Realty (NYSE:CDR) +14% on acquisition by Wheeler REIT. Eos Energy (NASDAQ:EOSE) +14%. Wheeler Real Estate (NASDAQ:WH...

BioLineRx Announces Additional Positive Results from Pharmacoeconomic Study Comparing Motixafortide + G-CSF to Plerixafor + G-CSF in Stem Cell Mobilization - Results demonstrate highly significant cost benefits of using Motixafortide in combination with G-CSF, versus plerixafor ...

BioLineRx Announces Completion of Enrollment of Phase 1/2a Study of Innovative Intratumoral Cancer Vaccine, AGI-134, in Unresectable Metastatic Solid Tumors - Initial results anticipated in the first half of 2022 PR Newswire TEL AVIV, Israel , Jan. 24, 2022 /...

If you’re looking for penny stocks to buy, there are a few “secret” ways to build your watch list. Over the weekend, we posted an article: 10 Secret Ways To Find The Best Penny Stocks To Buy In 2022 , and the first way to do so was by looking for news. This has beco...

BioLineRx Announces Successful Completion of Pre-NDA Meeting with FDA for Motixafortide for Stem Cell Mobilization in Multiple Myeloma Patients - NDA submission on track for H1 2022 PR Newswire TEL AVIV, Israel , Jan. 18, 2022 /PRNewswire/ -- BioLineRx L...

BioLineRx Provides Highlights from Oral Presentation Delivered at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition BioLineRx Provides Highlights from Oral Presentation Delivered at the 63rd American Society of Hematology (ASH) Annual Meeting & Ex...

BioLineRx Announces Formation of Immuno-Oncology Scientific Advisory Board (SAB) SAB will provide insight and guidance on the Company's immuno-oncology activities and is comprised of recognized leaders in the fields of cancer immunology, intra-tumoral injections and clinical dev...